NCT04567511View on ClinicalTrials.gov

Hemlibra in Mild Hemophilia A

PHASE4RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2027

Conditions

Factor VIII Deficiency, Congenital

Interventions

DRUG

Emicizumab

bispecific monoclonal antibody binding to activated Factor IX and Factor X

Trial Locations (1)

46260

RECRUITING

Indiana Hemophila @Thrombosis Center, Indianapolis

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Indiana Hemophilia &Thrombosis Center, Inc.

OTHER